Localisation and modulation of prostanoid receptors EP1 and EP4 in the rat chronic constriction injury model of neuropathic pain.
Immunohistochemistry was used to examine the expression of prostaglandin E(2) receptors EP1 and EP4 in sciatic nerves from the rat chronic constriction injury (CCI) model of neuropathic pain. At 21 days post-surgery the CCI rats had developed mechanical hyperalgesia on the operated side, and quantitative image analysis showed a highly significant doubling of the area occupied by EP1- and EP4-positive pixels in sections from CCI nerves when compared to sham-operated controls. Co-localisation studies with the marker ED1 revealed that 73% of the EP1-positive cells and 54% of the EP4-positive cells in the injured nerves represented infiltrating macrophages. Cells negative for ED1 and positive for either EP1 or EP4 were characterised as Schwann cells from their morphology and expression of myelin basic protein and S100 antigens. Similar EP1- and EP4-positive Schwann cell profiles were observed in sections of uninjured control nerves. Low levels of EP receptor expression were found in neurofilament-immunostained axons, but no consistent differences were observed in the levels of axonal EP staining between CCI and control tissue. These data provide further evidence of the importance of prostaglandins in the pathogenesis of neuropathic pain, and suggest that not only infiltrating macrophages but also Schwann cells may be involved in the modulation of these mediators in response to nerve injury.
Woodhams
Peter L
PL
Pain Research Department, Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park North, Harlow, Essex, UK. peter_l_woodhams@gsk.com
MacDonald
Rachel E
RE
Collins
Sue D
SD
Chessell
Iain P
IP
Day
Nicola C
NC
D000818:Animals; D001369:Axons / Q000378:metabolism; D002634:Chemotaxis, Leukocyte / Q000276:immunology; D002908:Chronic Disease; D004195:Disease Models, Animal; D007150:Immunohistochemistry; D007249:Inflammation / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D008026:Ligation / Q000009:adverse effects; D008264:Macrophages / Q000166:cytology / Q000378:metabolism*; D008297:Male; D004676:Myelin Basic Protein / Q000378:metabolism; D009437:Neuralgia / Q000378:metabolism / Q000503:physiopathology; D010523:Peripheral Nervous System Diseases / Q000378:metabolism* / Q000503:physiopathology; D011453:Prostaglandins / Q000378:metabolism; D051381:Rats; D018078:Receptors, Prostaglandin E / Q000378:metabolism*; D058306:Receptors, Prostaglandin E, EP1 Subtype; D058309:Receptors, Prostaglandin E, EP4 Subtype; D009418:S100 Proteins / Q000378:metabolism; D012583:Schwann Cells / Q000166:cytology / Q000378:metabolism*; D020426:Sciatic Neuropathy / Q000378:metabolism / Q000503:physiopathology; D015854:Up-Regulation / Q000502:physiology
D004676:Myelin Basic Protein; D011453:Prostaglandins; C545637:Ptger1 protein, rat; C545652:Ptger4 protein, rat; D018078:Receptors, Prostaglandin E; D058306:Receptors, Prostaglandin E, EP1 Subtype; D058309:Receptors, Prostaglandin E, EP4 Subtype; D009418:S100 Proteins